{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T08:19:22Z","timestamp":1771489162651,"version":"3.50.1"},"reference-count":60,"publisher":"American Society of Hematology","issue":"17","license":[{"start":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T00:00:00Z","timestamp":1687219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma having a poor overall survival that is in need for the development of new therapeutics. In this study, we report the identification and expression of a new isoform splice variant of the tyrosine kinase receptor AXL in MCL cells. This new AXL isoform, called AXL3, lacks the ligand-binding domain of the commonly described AXL splice variants and is constitutively activated in MCL cells. Interestingly, functional characterization of AXL3, using CRISPR inhibition, revealed that only the knock down of this isoform leads to apoptosis of MCL cells. Importantly, pharmacological inhibition of AXL activity resulted in a significant decrease in the activation of well-known proproliferative and survival pathways activated in MCL cells (ie, \u03b2-catenin, Ak strain transforming, and NF-\u03baB). Therapeutically, preclinical studies using a xenograft mouse model of MCL indicated that bemcentinib is more effective than ibrutinib in reducing the tumor burden and to increase the overall survival. Our study highlights the importance of a previously unidentified AXL splice variant in cancer and the potential of bemcentinib as a targeted therapy for MCL.<\/jats:p>","DOI":"10.1182\/blood.2022015581","type":"journal-article","created":{"date-parts":[[2023,6,20]],"date-time":"2023-06-20T21:55:53Z","timestamp":1687298153000},"page":"1478-1493","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":8,"title":["Inhibition of a new AXL isoform, AXL3, induces apoptosis of mantle cell lymphoma cells"],"prefix":"10.1182","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2434-8987","authenticated-orcid":false,"given":"Pascal","family":"Gelebart","sequence":"first","affiliation":[{"name":"1Department of Clinical Science, University of Bergen, Bergen, Norway"},{"name":"2Department of Hematology, Haukeland University Hospital, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-2828-7768","authenticated-orcid":false,"given":"May","family":"Eriksen Gjerstad","sequence":"additional","affiliation":[{"name":"1Department of Clinical Science, University of Bergen, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susanne","family":"Benjaminsen","sequence":"additional","affiliation":[{"name":"1Department of Clinical Science, University of Bergen, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3976-6412","authenticated-orcid":false,"given":"Jianhua","family":"Han","sequence":"additional","affiliation":[{"name":"1Department of Clinical Science, University of Bergen, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ida","family":"Karlsen","sequence":"additional","affiliation":[{"name":"1Department of Clinical Science, University of Bergen, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireia Mayoral","family":"Safont","sequence":"additional","affiliation":[{"name":"1Department of Clinical Science, University of Bergen, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Calum","family":"Leitch","sequence":"additional","affiliation":[{"name":"1Department of Clinical Science, University of Bergen, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zinayida","family":"Fandalyuk","sequence":"additional","affiliation":[{"name":"1Department of Clinical Science, University of Bergen, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihaela","family":"Popa","sequence":"additional","affiliation":[{"name":"1Department of Clinical Science, University of Bergen, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Helgeland","sequence":"additional","affiliation":[{"name":"3Department of Pathology, Haukeland University Hospital, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5025-3087","authenticated-orcid":false,"given":"Bela","family":"Papp","sequence":"additional","affiliation":[{"name":"4INSERM, UMR U976, Institut Saint-Louis, Paris, France"},{"name":"5Institut de Recherche Saint-Louis, H\u00f4pital Saint-Louis, Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3723-2927","authenticated-orcid":false,"given":"Fanny","family":"Baran-Marszak","sequence":"additional","affiliation":[{"name":"6INSERM U978, University of Paris 13, Bobigny, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-4625","authenticated-orcid":false,"given":"Emmet","family":"McCormack","sequence":"additional","affiliation":[{"name":"1Department of Clinical Science, University of Bergen, Bergen, Norway"},{"name":"2Department of Hematology, Haukeland University Hospital, Bergen, Norway"},{"name":"7Department of Clinical Science, Center for Pharmacy, University of Bergen, Bergen, Norway"},{"name":"8Department of Clinical Science, Center for Cancer Biomarkers, University of Bergen, Bergen, Norway"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"10","key":"2023102615211488300_bib1","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1172\/JCI61272","article-title":"Molecular pathogenesis of mantle cell lymphoma","volume":"122","author":"Jares","year":"2012","journal-title":"J\u00a0Clin Invest"},{"issue":"10","key":"2023102615211488300_bib2","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1038\/nrc2230","article-title":"Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics","volume":"7","author":"Jares","year":"2007","journal-title":"Nat Rev Cancer"},{"issue":"4","key":"2023102615211488300_bib3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrc1589","article-title":"Mechanisms of B-cell lymphoma pathogenesis","volume":"5","author":"Kuppers","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"suppl 1","key":"2023102615211488300_bib4","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/hon.2399","article-title":"The 2016 updated WHO classification of lymphoid neoplasias","volume":"35","author":"Quintanilla-Martinez","year":"2017","journal-title":"Hematol Oncol"},{"issue":"20","key":"2023102615211488300_bib5","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2023102615211488300_bib6","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1080\/10428190801947559","article-title":"Molecular genetic characterization reveals new subsets of mantle cell lymphoma","volume":"49","author":"Thelander","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"2023102615211488300_bib7","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.1182\/blood-2008-02-139212","article-title":"Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma","volume":"112","author":"Gelebart","year":"2008","journal-title":"Blood"},{"issue":"14","key":"2023102615211488300_bib8","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1038\/s41388-020-1183-x","article-title":"Stabilization of beta-catenin upon B-cell receptor signaling promotes NF-kB target genes transcription in mantle cell lymphoma","volume":"39","author":"Lazarian","year":"2020","journal-title":"Oncogene"},{"issue":"1","key":"2023102615211488300_bib9","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s13045-018-0621-5","article-title":"NF-kappaB signaling and its relevance to the treatment of mantle cell lymphoma","volume":"11","author":"Balaji","year":"2018","journal-title":"J\u00a0Hematol Oncol"},{"issue":"1","key":"2023102615211488300_bib10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/nm.3435","article-title":"Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma","volume":"20","author":"Rahal","year":"2014","journal-title":"Nat Med"},{"issue":"5","key":"2023102615211488300_bib11","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1182\/blood-2006-04-015586","article-title":"Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma","volume":"108","author":"Rudelius","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2023102615211488300_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1593\/tlo.10172","article-title":"Interleukin 22 signaling promotes cell growth in mantle cell lymphoma","volume":"4","author":"Gelebart","year":"2011","journal-title":"Transl Oncol"},{"issue":"1","key":"2023102615211488300_bib13","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood.V99.1.238","article-title":"ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances","volume":"99","author":"Camacho","year":"2002","journal-title":"Blood"},{"issue":"4","key":"2023102615211488300_bib14","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1182\/blood-2017-04-776740","article-title":"SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma","volume":"130","author":"Balsas","year":"2017","journal-title":"Blood"},{"issue":"18","key":"2023102615211488300_bib15","doi-asserted-by":"crossref","first-page":"3783","DOI":"10.1182\/blood-2012-04-424630","article-title":"Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells","volume":"120","author":"Zhang","year":"2012","journal-title":"Blood"},{"issue":"12","key":"2023102615211488300_bib16","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1182\/blood-2012-06-438937","article-title":"SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma","volume":"121","author":"Vegliante","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2023102615211488300_bib17","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood-2013-02-480418","article-title":"SOX11 is a mantle cell lymphoma oncogene","volume":"121","author":"Ferrando","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2023102615211488300_bib18","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/nrc.2017.121","article-title":"Targeting B cell receptor signalling in cancer: preclinical and clinical advances","volume":"18","author":"Burger","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"2023102615211488300_bib19","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"2023102615211488300_bib20","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2015-03-635326","article-title":"Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results","volume":"126","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"30","key":"2023102615211488300_bib21","doi-asserted-by":"crossref","first-page":"48692","DOI":"10.18632\/oncotarget.8961","article-title":"Mantle cell lymphoma in the era of precision medicine-diagnosis, biomarkers and therapeutic agents","volume":"7","author":"Inamdar","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"2023102615211488300_bib22","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1080\/10428194.2022.2086244","article-title":"Targeting the immune microenvironment in mantle cell lymphoma: implications for current and emerging therapies","volume":"63","author":"Qualls","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2023102615211488300_bib23","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13045-020-00914-1","article-title":"Emerging therapies in mantle cell lymphoma","volume":"13","author":"Hanel","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"issue":"10277","key":"2023102615211488300_bib24","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1016\/S0140-6736(21)00224-5","article-title":"Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1\/2 study","volume":"397","author":"Mato","year":"2021","journal-title":"Lancet"},{"issue":"14","key":"2023102615211488300_bib25","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"2023102615211488300_bib26","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/2040620715592569","article-title":"Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion","volume":"6","author":"Stephens","year":"2015","journal-title":"Ther Adv Hematol"},{"issue":"6","key":"2023102615211488300_bib27","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1093\/annonc\/mdv111","article-title":"Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes","volume":"26","author":"Cheah","year":"2015","journal-title":"Ann Oncol"},{"issue":"10","key":"2023102615211488300_bib28","first-page":"5016","article-title":"Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase","volume":"11","author":"O'Bryan","year":"1991","journal-title":"Mol Cell Biol"},{"issue":"3 Suppl 3","key":"2023102615211488300_bib29","first-page":"34","article-title":"Axl, a novel receptor tyrosine kinase isolated from chronic myelogenous leukemia","volume":"30","author":"Neubauer","year":"1993","journal-title":"Semin Hematol"},{"key":"2023102615211488300_bib30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0065-230X(08)00002-X","article-title":"TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer","volume":"100","author":"Linger","year":"2008","journal-title":"Adv Cancer Res"},{"issue":"19","key":"2023102615211488300_bib31","doi-asserted-by":"crossref","first-page":"8818","DOI":"10.18632\/oncotarget.2422","article-title":"Axl as a mediator of cellular growth and survival","volume":"5","author":"Axelrod","year":"2014","journal-title":"Oncotarget"},{"issue":"6220","key":"2023102615211488300_bib32","doi-asserted-by":"crossref","first-page":"1260419","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhlen","year":"2015","journal-title":"Science"},{"issue":"6","key":"2023102615211488300_bib33","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood-2010-09-305649","article-title":"The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy","volume":"117","author":"Ghosh","year":"2011","journal-title":"Blood"},{"issue":"6","key":"2023102615211488300_bib34","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1182\/blood.V84.6.1931.1931","article-title":"Expression of axl, a transforming receptor tyrosine kinase, in normal and malignant hematopoiesis","volume":"84","author":"Neubauer","year":"1994","journal-title":"Blood"},{"issue":"1","key":"2023102615211488300_bib35","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/sj.emboj.7600912","article-title":"Structural basis for Gas6-Axl signalling","volume":"25","author":"Sasaki","year":"2006","journal-title":"Embo\u00a0j"},{"issue":"10","key":"2023102615211488300_bib36","doi-asserted-by":"crossref","first-page":"e266","DOI":"10.1038\/oncsis.2016.66","article-title":"Axl-EGFR receptor tyrosine kinase hetero-interaction provides EGFR with access to pro-invasive signalling in cancer cells","volume":"5","author":"Vouri","year":"2016","journal-title":"Oncogenesis"},{"issue":"4","key":"2023102615211488300_bib37","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/bjc.2016.428","article-title":"Giving AXL the axe: targeting AXL in human malignancy","volume":"116","author":"Gay","year":"2017","journal-title":"Br J Cancer"},{"issue":"14","key":"2023102615211488300_bib38","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1182\/blood-2013-03-491431","article-title":"Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma","volume":"122","author":"Ben-Batalla","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2023102615211488300_bib39","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1073\/pnas.0909333107","article-title":"Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival","volume":"107","author":"Gjerdrum","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2023102615211488300_bib40","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1158\/1078-0432.CCR-12-1558","article-title":"An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance","volume":"19","author":"Byers","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"8","key":"2023102615211488300_bib41","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1021\/acs.jmedchem.5b01273","article-title":"AXL inhibitors in cancer: a medicinal chemistry perspective","volume":"59","author":"Myers","year":"2016","journal-title":"J\u00a0Med Chem"},{"issue":"11","key":"2023102615211488300_bib42","doi-asserted-by":"crossref","first-page":"a009076","DOI":"10.1101\/cshperspect.a009076","article-title":"Biology of the TAM receptors","volume":"5","author":"Lemke","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"47","key":"2023102615211488300_bib43","doi-asserted-by":"crossref","first-page":"5405","DOI":"10.1038\/onc.2013.487","article-title":"Preclinical validation of AXL receptor as a target for antibody-based pancreatic cancer immunotherapy","volume":"33","author":"Leconet","year":"2014","journal-title":"Oncogene"},{"issue":"2","key":"2023102615211488300_bib44","doi-asserted-by":"crossref","first-page":"e1263716","DOI":"10.1080\/23723556.2016.1263716","article-title":"Targeting the AXL signaling pathway in ovarian cancer","volume":"4","author":"Huang","year":"2017","journal-title":"Mol Cell Oncol"},{"issue":"11","key":"2023102615211488300_bib45","doi-asserted-by":"crossref","first-page":"2806","DOI":"10.1158\/1078-0432.CCR-16-1316","article-title":"Therapeutic activity of anti-AXL antibody against triple-negative breast cancer patient-derived xenografts and metastasis","volume":"23","author":"Leconet","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"9","key":"2023102615211488300_bib46","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1038\/sj.leu.2401484","article-title":"Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"13","author":"Rochlitz","year":"1999","journal-title":"Leukemia"},{"issue":"2","key":"2023102615211488300_bib47","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jmb.2006.10.017","article-title":"Structural insights into fibronectin type III domain-mediated signaling","volume":"367","author":"Bencharit","year":"2007","journal-title":"J\u00a0Mol Biol"},{"issue":"50","key":"2023102615211488300_bib48","doi-asserted-by":"crossref","first-page":"31447","DOI":"10.1074\/jbc.272.50.31447","article-title":"Fibronectin type III repeats mediate RGD-independent adhesion and signaling through activated beta1 integrins","volume":"272","author":"Chi-Rosso","year":"1997","journal-title":"J\u00a0Biol Chem"},{"issue":"8","key":"2023102615211488300_bib49","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1042\/CS20110411","article-title":"Axl-dependent signalling: a clinical update","volume":"122","author":"Korshunov","year":"2012","journal-title":"Clin Sci"},{"issue":"7793","key":"2023102615211488300_bib50","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41586-020-1970-0","article-title":"Genomic basis for RNA alterations in cancer","volume":"578","author":"Calabrese","year":"2020","journal-title":"Nature"},{"issue":"11","key":"2023102615211488300_bib51","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1182\/blood-2016-06-720516","article-title":"A\u00a0novel PTPN1 splice variant upregulates JAK\/STAT activity in classical Hodgkin lymphoma cells","volume":"129","author":"Zahn","year":"2017","journal-title":"Blood"},{"issue":"9","key":"2023102615211488300_bib52","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1158\/2159-8290.CD-19-1436","article-title":"Posttranslational regulation of the exon skipping machinery controls aberrant splicing in leukemia","volume":"10","author":"Zhou","year":"2020","journal-title":"Cancer Discov"},{"issue":"11","key":"2023102615211488300_bib53","doi-asserted-by":"crossref","first-page":"874","DOI":"10.18632\/oncotarget.360","article-title":"Mechanisms of AXL overexpression and function in Imatinib-resistant chronic myeloid leukemia cells","volume":"2","author":"Dufies","year":"2011","journal-title":"Oncotarget"},{"issue":"1","key":"2023102615211488300_bib54","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/path.4561","article-title":"CBL controls a tyrosine kinase network involving AXL, SYK and LYN in nilotinib-resistant chronic myeloid leukaemia","volume":"237","author":"Gioia","year":"2015","journal-title":"J\u00a0Pathol"},{"issue":"2","key":"2023102615211488300_bib55","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/jid.2010.326","article-title":"Axl promotes cutaneous squamous cell carcinoma survival through negative regulation of pro-apoptotic Bcl-2 family members","volume":"131","author":"Papadakis","year":"2011","journal-title":"J\u00a0Invest Dermatol"},{"issue":"1","key":"2023102615211488300_bib56","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/nrm.2016.132","article-title":"Post-transcriptional gene regulation by mRNA modifications","volume":"18","author":"Zhao","year":"2017","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"2023102615211488300_bib57","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.stem.2016.01.022","article-title":"CRISPR interference efficiently induces specific and reversible gene silencing in human iPSCs","volume":"18","author":"Mandegar","year":"2016","journal-title":"Cell Stem Cell"},{"issue":"8","key":"2023102615211488300_bib58","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.celrep.2015.02.002","article-title":"An inducible lentiviral guide RNA platform enables the identification of tumor-essential genes and tumor-promoting mutations in\u00a0vivo","volume":"10","author":"Aubrey","year":"2015","journal-title":"Cell Rep"},{"issue":"13","key":"2023102615211488300_bib59","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2023102615211488300_bib60","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa2201817","article-title":"Ibrutinib plus bendamustine and rituximab in untreated mantle-cell lymphoma","volume":"386","author":"Wang","year":"2022","journal-title":"N\u00a0Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/17\/1478\/2085638\/blood_bld-2022-015581-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/17\/1478\/2085638\/blood_bld-2022-015581-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T15:22:29Z","timestamp":1698333749000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/142\/17\/1478\/496468\/Inhibition-of-a-new-AXL-isoform-AXL3-induces"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":60,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2023,10,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022015581","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]}}}